Dr. John Mascarenhas on the COMFORT-I/II Studies for Ruxolitinib in Myelofibrosis
The studies examined ruxolitinib compared to placebo in the United States (COMFORT-I) and best available therapy in Europe (COMFORT-II) for patients with myelofibrosis.
John Mascarenhas, MD, associate professor of medicine, Mount Sinai Hospital, discusses the COMFORT-I and COMFORT-II studies. The studies examined ruxolitinib compared to placebo in the United States (COMFORT-I) and best available therapy in Europe (COMFORT-II) for patients with myelofibrosis. In both studies ruxolitinib reduced splenomegaly and improving symptoms, mostly by down-modulating inflammitory cytokine signaling.
Exploring Factors Supporting TKI Discontinuation in Patients With Ph+ ALL
June 27th 2025Recent studies reveal promising outcomes for discontinuing TKI therapy in select patients with Philadelphia chromosome-positive acute lymphoblastic leukemia, suggesting potential long-term remission.
Read More
